Behçet's disease: An update on the pathogenesis

Clinical and Experimental Rheumatology

Volumn 19, Issue 5 SUPPL. 24, 2001, Pages

  Gul A ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

T cell; Beh et's disease; Complex genetic disease; Cytokines; Endothelial activation; Heat shock proteins; HLA B51; Pathergy; Thrombotic tendency; Tumor necrosis factor; Vasculitis

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B ANTIGENS; HLA BW51; HLA-BW51; MICA PROTEIN;

BEHCET DISEASE; EDITORIAL; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

BEHCET SYNDROME; ENDOTHELIUM, VASCULAR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B ANTIGENS; HUMAN; LINKAGE (GENETICS); POLYMORPHISM (GENETICS); T-LYMPHOCYTES;

EID: 17844372694     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. N Engl J Med 1999; 341: 1284-91.
2. YAZICI H, YURDAKUL S, HAMURYUDAN V: Behçet's syndrome. Curr Opin Rheum 1999; 11: 53-7.
3. LEHNER T: The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol 1997; 14: 21-32.
4. SAKANE T, SUZUKI N, NAGAFUCHI H: Etiopathology of Behcet's disease: immunological aspects. Yonsei Med J 1997; 38: 350-8.
5. LEHNER T: Immunopathogenesis of Behcet's disease. Ann Med Interne (Paris) 1999; 150: 483-7.
6. VERITY DH, MARR JE, OHNO S, WALLACE GR, STANFORD MR: Behçet's disease, the Silk Road and HLA-B51: Historical and geographical perspectives. Tissue Antigens 1999; 54: 213-20.
7. OHNO S, OHGUCHI M, HIROSE S, MATSUDA H, WAKISAKA A, AIZAWA M: Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982; 100: 1455-8.
8. COMAS D, CALAFELL F, MATEU E, et al.: Trading genes along the Silk Road: mtDNA sequences and the origin of Central Asian populations. Am J Hum Genet 1998; 63: 1824-38.
9. GÜL A, INANÇ M, OCAL L, ARAL O, KONIÇE M: Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 2000; 59: 622-5.
10. KONÉ-PAUT I, GEISLER I, WECHSLER B, et al.: Familial agregation in Behçet's disease: High frequency in siblings and parents of pediatric probands. J Pediatr 1999; 135: 89-93.
11. BIRD STEWART JA: Genetic analysis of families of patients with Behçet's syndrome: Data incompatible with autosomal recessive inheritance. Ann Rheum Dis 1986; 45: 265-8.
12. FRESKO I, SOY M, HAMURYUDAN V, et al.: Genetic anticipation in Behçet's syndrome. Ann Rheum Dis 1998; 57: 45-8.
13. MIZUKI N, INOKO H, OHNO S: Pathogenic gene responsible for the predisposition to Behçet's disase. Intern Rev Immunol 1997; 14: 33-48.
14. MIZUKI N, INOKO H, SUGIMURA K, et al.: RFLP analysis in the TNF-β gene and the susceptibility to alloreactive NK cells in Behçet's disease. Invest Ophthalmol Vis Sci 1992; 33: 3084-90.
15. MIZUKI M, OHNO S, SATO T, et al.: Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behcet's disease. Hum Immunol 1995; 43: 129-35.
16. VERITY DH, WALLACE GR, VAUGHAN RW, et al.: HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behçet's disease. Tissue Antigens 1999; 54: 264-72.
17. MIZUKI N, OTA M, KIMURA M, et al.: Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet's disease. Proc Natl Acad Sci USA 1997; 94: 1298-303.
18. GROH V, STEINLE A, BAUER S, SPIES T: Recognition of stress-induced MHC molecules by intestinal epithelial γδ cells. Science 1998; 279: 1737-40.
19. ZWIRNER NW, DOLE K, STASTNY P: Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 1999; 60: 323-30.
20. OTA M, MIZUKI N, KATSUYAMA Y, et al.: The critical region for Behçet's disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999; 64: 1406-10.
21. MIZUKI N, OTA M, KATSUYAMA Y, et al.: Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Anhritis Rheum 1999; 42: 1961-6.
22. WALLACE GR, VERITY DH, DELAMAINE LJ, et al.: MIC-A allele profiles and HLA class I associations in Behçet's disease. Immunogenetics 1999; 49: 613-17.
23. MIZUKI N, OTA M, YABUKI K, et al.: Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 2000; 41: 3702-8.
24. PERVIN K, CHILDERSTONE A, SHINNICK T, et al.: T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol 1993; 151: 1-10.
25. MIZUKI N, INOKO H, ANDO H, et al.: Behçet's disease associated with one of the HLA-B51 subantigens, HLA-B*5101. Am J Ophthalmol 1993; 116: 406-9.
26. MIZUKI N, INOKO H, ISHIHARA M, et al.: A complete type patient with Behçet's disease associated with HLA-B*5102. Acta Ophthalmologica 1994; 72: 757-8.
27. MIZUKI N, OHNO S, ANDO H, et al.: A strong association of HLA-B*5101 with Behçet's disease in Greek patients. Tissue Antigens 1997; 50: 57-60.
28. KERA J, MIZUKIN, OTA M, et al.: Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behçet's disease in Italian patients. Tissue Antigens 1999; 54: 565-71.
29. WILDNER G, THURAU SR: Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to a major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994; 24: 2579-85.
30. THURAU SR, DIEDRICHS-MÖHRING M, FRICKE H, ARBOGAST S, WILDNER G: Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis patients with an MHC-peptide cross-reactive with autoantigen-first results. Immunol Letters 1997; 57: 193-201.
31. KURHAN-YAVUZ S, DIRESKENELI H, BOZKURT N, et al.: Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with restinal-S antigen in patients with uveitis. Clin Exp Immunol 2000; 120: 162-6.
32. LITWIN V, GUMPERZ J, PARHAM P, PHILLIPS JH, LANIER LL: NKB1: A natural killer cell receptor involved in the recognition of polymorhic HLA-B molecules. J Exp Med 1994; 180: 537-43.
33. CELLA M, LONGO A, FERRARA GB, STROMINGER JL, COLONNA M: NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994; 180: 1235-42.
34. LANIER LL: NK cell receptors. Ann Rev Immunol 1998; 16: 359-93.
35. MINGARI MC, MORETTA A, MORETTA L: Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T cell responses. Immunol Today 1998; 19: 153-7.
36. GÜL A, UYAR FA, INANÇ M, et al.: A weak association of HLA-B*2702 with Behçet's disease in Turkey (abstract). Yonsei Med J 2000; 41 (Suppl): 38.
37. TAKENO M, KARIYONE A, YAMASHITA N, et al.: Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995; 38: 426-33.
38. SENSI A, GAVIOLI R, SPISANI S, et al.: HLA B51 antigen associated with neutrophil hyper-reactivity. Dis Markers 1991; 9: 327-31.
39. GÜL A, HAJEER AH, WORTHINGTON J, BARRET JH, OLLIER WER, SILMAN AJ: Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001; 44: 239-41.
40. GÜL A, HAJEER AH, WORTHINGTON J, OLLIER B, SILMAN AJ: Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum 2001 (in press).
41. BEHÇET H: Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatologische Wochenschrift 1937; 105: 1152-7.
42. SEZER FN: The isolation of a virus as the cause of Behçet's disease. Am J Ophthalmol 1953; 36: 301-15.
43. EVANS AD, PALLIS CA, SPILLANE JD: Involvement of the nervous system in Behçet's syndrome: report of three cases and isolation of virus. Lancet 1957; 2:349-53.
44. MORTADA A, IMAM IZE: Virus aetiology of Behçet's disease. Br J Ophthalmol 1964; 48: 250-9.
45. EGLIN RP, LEHNER T, SUBAK-SHARPE JH: Detection of RNA complementary to herpes simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet 1982; 2: 1356-61.
46. STUDD M, MCCANCE DJ, LEHNER T: Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991; 34: 39-43.
47. LEE S, BANG D, CHO YH, LEE ES, SOHN S: Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res 1996; 288: 179-83.
48. SOHN S: Etiopathology of Behçet's disease; Herpes simplex virus infection and animal model. Yonsei Med J 1997; 38: 359-64.
49. SOHN S, LEE ES, BANG D, LEE S: Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998; 8: 21-3.
50. MIZUSHIMA Y, MATSUDAT, HOSHI K, et al.: Induction of Behçet's disease symptoms following dental treatment and streptococcal antigen skin test. J Rheumatol 1998; 15: 1029-30.
51. THE BEHÇET'S DISEASE RESEARCH COMMITTEE OF JAPAN: Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behçet's disease-A multicenter study. J Rheumatol 1989; 16: 506-11.
52. MIZUSHIMA Y: Streptococcus and Behçet's disease. In: O'DUFFY JD, KOKMEN E (Eds.): Behçet's Disease: Basic and Clinical Aspects. New York, Marcel Dekker, Inc., 1991: 421-6.
53. AOKI K, OHNO S: Studies on the constitution and past history of patients with Behçet's disease. Acta Soc Ophthalmol Jpn 1972; 76: 1608-12.
54. COOPER C, PIPPARD EC, SHARP H, WICKHAM C, CHAMBERLAIN MA, BARKER DJP: Is Behçet's disease triggered by childhood infection ? Ann Rheum Dis 1989; 48: 421-3.
55. ISOGAI E, ISOGAI H, YOSHIKAWA K, et al.: Microbial ecology of oral flora in Behçet's disease. In: O'DUFFY JD, KOKMEN E (Eds.): Behçet's Disease: Basic and Clinical Aspects, New York, Marcel Dekker, Inc., 1991: 405-14.
56. NARIKAWA S, SUZUKI Y, TAKAHASHI M, FURUKAWA A, SAKANE T, MIZUSHIMA Y: Streptococcus oralis previously identified as uncommon Streptococcus sanguis in Behçet's disease. Arch Oral Biol 1995; 40: 685-90.
57. LEHNER T, LAVERY E, SMITH R, VAN DER ZEE R, MIZUSHIMA Y, SHINNICK T: Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infect Immun 1991; 59: 1434-41.
58. KANEKO S, SUZUKI N, YAMASHITA N, et al.: Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol 1997; 108: 204-12.
59. DIRESKENELI H, EKSIOGLU-DEMIRALP E, YAVUZ S, et al.: T cell responses to 60/65 kDa heat shock protein derived peptides in Turkish patients with Behçet's disease. J Rheumatol 2000; 27: 708-13.
60. STANFORD MR, KASP E, WHISTON R, et al.: Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats. Clin Exp Immunol 1994; 97: 226-31.
61. HU W, HASAN A, WILSON A, et al.: Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol 1998; 28: 2444-55.
62. GÜL A, ESIN S, DILSEN N, KONIÇE M, WIGZELL H, BIBERFELD P: Immunohistology of skin pathergy reaction in Behçet's disease. Br J Dermatol 1995; 132: 901-7.
63. HIROHOTA S, HASHIMOTO T: Abnormal T cell responses to bacterial superantigens in Behçet's disease. Clin Exp Immunol 1998; 112: 317-24.
64. MEGE J-L, DILSEN N, SANGUEDOLCE V, et al.: Overproduction of monocyte derived tumor necrosis factor a, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
65. FREYSDOTTIR J, LAU S-H, FORTUNE F: γδ T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118: 451-7.
66. FRASSANITO MA, DAMMACCO R, CAFFORIO P, DAMMACCO F: Th1 polarization of the immune response in Behçet's disease. Arthritis Rheum 1999; 42: 1967-74.
67. NIWA Y, MIYAKE S, SAKANE T, et al.: Auto-oxidative damage in Behçet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49: 247-255.
68. SAHIN S, AKOGLU T, DIRESKENELI H, SEN LS, LAWRENCE R: Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. Ann Rheum Dis 1996; 55: 128-33.
69. th International Congress on Behçet's Disease. Reggio Emilia, Italy, 7-9 October 1998. Program and Abstracts: 56.
70. th International Congress on Behçet's Disease. Reggio Emilia, Italy, 7-9 October 1998. Program and Abstracts: 57.
71. ESIN S, GÜL A, HODARA V, et al.: Peripheral blood T cell expansions in patients with Behçet's disease. Clin Exp Immunol 1997; 107: 520-7.
72. YAMASHITA N, KANEOKA H, KANEKO S, et al.: Role of γδ T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997; 107: 241-247.
73. FORTUNE F, WALKER J, LEHNER T: The expression of γδ T cell receptor and the prevalence of primed, activated and Ig-A bound T cells in Behçet's syndrome. Clin Exp Immunol 1990; 82: 326-32.
74. HASAN A, FORTUNE F, WILSON A, et al.: Role of γδ T cells in the pathogenesis and diagnosis of Behçet's disease. Lancet 1996; 347: 789-94.
75. POULTER LW, LEHNER T: Immunohistology of oral lesions from patients with recurrent oral ulcers and Behçet's syndrome. Clin Exp Immunol 1989; 78: 189-95.
76. CHARTERIS DG, BARTON K, McCARTNEY ACE, et al.: CD4+ lymphocyte involvement in ocular Behçet' disease. Autoimmunity 1992; 12: 201-6.
77. SUGI-IKAI N, NAKAZAWA M, NAKAMURA S, OHNO S, MINAI M: Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998; 39: 996-1004.
78. +) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol 1994; 24: 1536-43.
79. NIWA Y, MIZUSHIMA Y: Neutrophil-potentiating factors released from stimulated lymphocytes; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behçet's disease. Clin Exp Immunol 1990; 79: 353-60.
80. HIROHATA S, OKA H, MIZUSHIMA Y: Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behçet's disease. Cell Immunol 1992; 140: 410-9.
81. TANAKA T, YAMAKAWA N, KOIKE N, SUZUKI J, MIZUNO F, USUI M: Behcet's disease and antibody titers to various heat-shock protein 60s. Ocul Immunol Inflamm 1999; 7: 69-74.
82. SUZUKI N, SAKANE T, UEDA Y, TSUNEMATSU T, et al.: Abnormal B cell function in patients with Behçet's disease. Arthritis Rheum 1986; 29: 212-9.
83. EKSIOGLU-DEMIRALP E, KIBAROGLU A, DIRESKENELI H, et al.: Phenotypic characteristics of B cells in Behçet's disease: Increased activity in B cell subsets. J Rheumatol 1999; 26: 826-32.
84. DIRESKENELI H, HASAN A, SHINNICK T, et al.: Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease. Scand J Immimol 1996; 43: 464-71.
85. KANEKO F, TAKAHASHI Y, MURAMATSU R, et al.: Natural killer cell numbers and function in peripheral lymphoid cells in Behcet's disease. Br J Dermatol 1985; 113: 313-8.
86. SUZUKI Y, HOSHI K, MATSUDA T, MIZUSHIMA Y: Increased peripheral blood γδ+ T cells and natural killer cells in Behçet's disease. J Rheumatol 1992; 19: 588-92.
87. EKSIOGLU-DEMIRALP E, DIRESKENELI H, ERGUN T, FRESKO I, AKOGLU T: Increased CD4+CD16+ and CD4+CD56+ T cell subsets in Behçet's disease. Rheumatol Int 1999; 19: 23-26.
88. HAMZAOUI K, AYED K, HAMZA M, TOURAINE JL: Natural killer cells in Behcet's disease. Clin Exp Immunol 1988; 71: 126-31.
89. KANSU E, SAHIN G, SAHIN F, SIVRI B, SAYEK I, BATMAN F: Impaired prostacyclin synthesis by vessel walls in Behcet's disease. Lancet 1986; 2: 1154.
90. HAZNEDAROGLU IC, OZCEBE OI, OZDEMIR O, CELIK I, DUNDAR SV, KIRAZLI S: Impaired haemostatic kinetics and endothelial function in Behcet's disease. J Intern Med 1996; 240: 181-7.
91. HAZNEDAROGLU IC, OZDEMIR O, OZCEBE O, DUNDAR SV, KIRAZLI S: Circulating thrombomodulin as a clue of endothelial damage in Behcet's disease. Thromb Haemost 1996; 75: 974-5.
92. USLU T, EREM C, TOSUN M, DEGER O: Plasma endothelin-1 levels in Behcet's disease. Clin Rheumatol 1997; 16: 59-61.
93. GÜL A, ÖZBEK U, ÖZTÜRK C, INANÇ M, KONIÇE M, ÖZÇELIK T: Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatol 1996; 35: 1178-80.
94. GÜL A, ASLANTAS AB, TEKINAY T, KONIÇE M, ÖZÇELIK T: Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology 1999; 38: 1298-9.
95. VERITY DH, VAUGHAN RW, MADANAT W, et al.: Factor V Leiden mutation is associated with ocular involvement in Behcet's disease. Am J Ophthalmol 1999; 128: 352-6.
96. HULL RG, HARRIS EN, GHARAVI AE, et al.: Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 1984; 43: 746-8.
97. ZOUBOULIS CC, BUTTNER P, TEBBE B, ORFANOS CE: Anticardiolipin antibodies in Adamantiades-Behcet's disease. Br J Dermatol 1993; 128: 281-4.
98. MADER R, ZIV M, ADAWI M, MADER R, LAVI I: Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999; 26: 2404-8.
99. DIRESKENELI H, KESER G, D'CRUZ D, et al.: Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease. Clin Rheumatol 1995; 14: 55-61.
100. YAZICI H, TUZUN Y, PAZARLI H, et al.: Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
101. DILSEN N, KONIÇE M, ARAL O, ÖCAL L, INANC M, GÜL A: Risk factors for vital organ involvement in Behçet's disease. In WECHSLER B, GODEAU P (Eds.): Behçet's disease. Amsterdam, Excerpta Medica, 1993: 165-9.
102. SULLIVAN TR JR, KARAS RH, ARONOVITZ M, et al.: Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995; 96: 2482-8.
103. MIYAMOTO N, MANDAI M, SUZUMA I, SUZUMA K, KOBAYASHI K, HONDA Y: Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J Immunol 1999; 163: 374-9.